Traws Pharma Q2 FY26 net loss widens to $3.0 million; revenue logs no revenue

TRAW•2026-08-14

Program update

The company plans an MHRA resubmission for tivoxavir marboxil by the end of Q3 2026. CEO Iain Dukes said it is moving quickly on a revised toxicology package.

Quarterly results

Traws Pharma posted a Q2 net loss of $3.05 million, widening from a $915,000 loss a year earlier.

Revenue was no revenue, versus $2.73 million a year earlier, on non-recurring deferred revenue recognized in Q2 2025.

R&D expense fell 52.01% to $1.1 million, while G&A climbed more than doubled to $3.48 million.

Cash and cash equivalents rose to $5.02 million at June 30, up from $3.82 million at Dec. 31.

Traws Pharma Q2 FY26 net loss widens to $3.0 million; revenue logs no revenue

Program update

Quarterly results

Related News

BD CEO Thomas E. Polen Jr disposes of 43,278 common shares worth $8.03 million

OLB Group Q2 FY26 net loss narrows 50.35% to $1.05 million; revenue drops 43.6% to $1.28 million

Lightstone Value Plus REIT II Q2 FY26 swings to net income of $209,000; revenue rises 4.51% to $13.9 million

WD-40 Americas Division President Patricia Q. Olsem sells 200 shares for $46,944

ClearOne Q2 FY26 net loss from continuing operations narrows to $919,000; general and administrative expense falls 22% to $849,000